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Abstract As heart failure, coronary artery disease and
atrial fibrillation all bring a risk of thrombosis, anti-
thrombotic therapy is recommended. Despite such treat-
ment, major cardiovascular events such as myocardial
infarction and stroke still occur, implying inadequate sup-
pression of thrombus formation. Accordingly, identifica-
tion of patients whose haemostasis remains unimpaired by
treatment is valuable. We compared indices for assessing
thrombogenesis and fibrinolysis by two different tech-
niques in patients on different anti-thrombotic agents, i.e.
aspirin or warfarin. We determined fibrin clot formation
and fibrinolysis by a microplate assay and thromboelas-
tography, and platelet marker soluble P selectin in 181
patients with acute or chronic heart failure, coronary artery
disease who were taking either aspirin or warfarin. Five
thromboelastograph indices and four microplate assay
indices were different on aspirin versus warfarin
(p\ 0.05). In multivariate regression analysis, only
microplate assay indices rate of clot formation and rate of
clot dissolution were independently related to aspirin or
warfarin use (p B 0.001). Five microplate assay indices,
but no thrombelastograph index, were different (p\ 0.001)
in aspirin users. Three microplate assay indices were dif-
ferent (p B 0.002) in warfarin users. The microplate assay
indices of lag time and rate of clot formation were abnor-
mal in chronic heart failure patients on aspirin, suggesting
increased risk of thrombosis despite anti-platelet use. Sol-
uble P selectin was lower in patients on aspirin
(p = 0.0175) but failed to correlate with any other index of
haemostasis. The microplate assay shows promise as a tool
for dissecting thrombogenesis and fibrinolysis in cardio-
vascular disease, and the impact of antithrombotic therapy.
Prospective studies are required to determine a role in
predicting thrombotic risk.
Keywords Thrombelastograph  Thrombosis 
Fibrinolysis  Haemostasis
Introduction
The leading cause of mortality and morbidity in the
developed world is cardiovascular disease. Three of the
major manifestation of this disease are heart failure, whe-
ther presenting acutely or chronically, coronary artery
disease, and atrial fibrillation. Each of these conditions may
be present alone, or in concert, as they all share common
risk factors such as atherosclerosis, hypertension, diabetes
or chronic kidney disease. Furthermore, the development
of any one of these conditions is itself a precursor for future
development of the other two diseases. These three con-
ditions are also linked the development of other throm-
boembolic disease such as ischaemic stroke and systemic
thromboembolism (notable deep vein thrombosis and pul-
monary embolism) [1–4].
A key treatment of cardiovascular diseases is anti-
thrombotic therapy with antiplatelet agents such as aspirin
and clopidogrel, and with oral anticoagulants such as the
vitamin K antagonist (VKA) warfarin and non-VKA oral
anticoagulants (NOACs) [5–8]. However, although these
strategies are effective, there remains a considerable risk of
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additional thrombosis in patients on these drugs despite
best clinical practice. One strategy to improve clinical
outcome is to provide personalised thrombotic risk
assessment by assessing patients with or at increased risk
of thrombosis and then target those at highest clinical risk,
and/or identifying those in whom standardised antithrom-
botic therapy seems ineffective. In both these respects, the
laboratory can provide direct evidence of an increased risk
of thrombosis and the efficacy of anti-thrombotic drugs, the
international normalised ratio (INR) being the best exam-
ple, although this test is not optimum for assessing NOACs
[9–11]. However, although the INR provides essential
information on the effects of VKAs, it has limited scope,
leaving room for the development of other tests.
Whole blood and fibrin clot formation and lysis may
also be studied in vitro with devices such as the thrombe-
lastograph, and in a micro-titre plate assay, of which there
are several variants [12–14]. We have recently described
and validated an adaptation of the latter method for testing
haemostasis in vitro with a micro-plate assay, and have
compared it to the thrombelastograph [15]. The thrombe-
lastograph has been used clinically in examining the effects
of warfarin, heparin and the NOACs [16–19].
We hypothesised that the microplate assay is better able
to discriminate those patients with cardiovascular disease
(heart failure, atrial fibrillation, coronary artery disease) on
different antithrombotic treatments than is the thromboe-
lastograph. The standard antithrombotic treatment for atrial
fibrillation is oral anticoagulation (almost always warfarin),
which brings a disrupted coagulation system. Conversely,
coronary artery disease patients on aspirin should have
minimum alteration to their coagulation system, whereas
acute heart failure and chronic heart failure patients may be
on either treatment [7]. This allows comparisons of the
microplate assay with the thromboelastograph in subjects
on different antithrombotic therapies. To provide a per-
spective of acute compared to chronic, stable disease, we
recruited a small number of in-patients with acute heart
failure, and to perspective of platelet function and
haemostasis between those on aspirin and those on war-
farin, we measured levels of platelet marker soluble P
selectin, known to be increased in cardiovascular disease
[20].
Subjects, materials and methods
Subjects
Venous blood was obtained from 57 patients with chronic
heart failure, 20 patients with acute heart failure, 44
patients with coronary artery disease but no heart failure or
atrial fibrillation, and 60 patients with atrial fibrillation but
no heart failure or coronary artery disease, all of whom
were attending hospital as in-patients or as out-patients.
Exclusion criteria were aged \18 years, had active or
recent (\12 months) malignancy, active immunological
disease, pregnancy, chronic liver disease, recent or chronic
infections, chronic inflammatory disease, connective tissue
disease, recent stroke/acute coronary syndrome (within
2 months), active bleeding, recent arterial/venous throm-
bosis or recent surgery, known haemophilia or throm-
bophilia (such as Factor V Leiden, Protein C/S/
antithrombin deficiency, antiphospholipid syndrome), use
of an anti-platelet other than aspirin, use of a VKA other
than warfarin, or unable to give consent. Heart failure was
defined by recent, routine echocardiography within past
6 months and with a documented severe left ventricular
systolic dysfunction with ejection fraction B35 %, atrial
fibrillation by typical changes on routine 12-lead electro-
cardiogram, and coronary artery disease by previous
myocardial infarction ([12 months), coronary artery
bypass grafting, or[50 % stenosis of a least one coronary
artery defined by coronary angiogram. Standard clinical,
laboratory, and demographic data were collected (Table 1).
Local research ethics committee approval was obtained and
all participants gave written informed consent.
Laboratory
Citrated venous blood was collected and analysed for
indices of thrombogenesis and fibrinolysis using thrombe-
lastography and by a microplate assay [12, 15]. The
thrombelastograph assay uses whole blood, which is added
to a small rotating cuvette alongside an activating solution
of thromboplastin [16–19]. Formation of a clot is moni-
tored by the resistance offered by the clot to the vibration
of a probe. The microplate assay is conducted in plasma
and consists of two parts [15]. Firstly, in a thrombogenesis
assay, 25 ll plasma, 75 ll TRIS–NaCl buffer, and 50 ll
thrombin are added to the wells of 96-well microtitre plate.
Clot formation is followed for 30 min at 37 C in a micro-
titre plate reader by change in optical density (Fig. 1a). The
key endpoints are lag time (time from addition of thrombin
to the start of clot formation), rate of clot formation
(change in optical density over time), and clot density
(maximum change in optical density absorbance). Sec-
ondly, in the fibrinolysis assay, 75 ll plasma and 75 ll of a
TRIS–NaCl/calcium/thrombin/tissue plasminogen activa-
tor cocktail are added to the wells of 96-well microtitre
plate. Clot dissolution is followed for 30 min at 37 C in a
plate reader by change in optical density (Fig. 1b). The key
endpoints are rate of clot dissolution, being the change in
optical density over time on the downward slope of the
right hand portion of the graph, and the time for 50 %
fibrin clot lysis (T50).
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Although the thrombelastograph delivers numerous
indices, we determined the five that are most pertinent and
which have similarities to those of the microplate assay
[15]. The thrombelastograph R time and microplate assay
lag time both reflect time taken for thrombogenesis to
begin. The TEG K time marks time from the beginning of
clot formation to when a fixed level of clot firmness is
reached: there is no microplate assay equivalent of this
index. The thrombelastograph ‘Angle’ and the microplate
assay rate of clot formation both measure the rate clot
growth. The thromboelastograph maximum amplitude and
the microplate assay maximum optical density respectively
assess maximum strength, stiffness or density of the
developed clot, whilst the thrombelastograph LY30, and
the microplate assays of rate of clot dissolution and the T50
(time for 50 % of the clot to be lysed) all provide indices of
the ability of the formed clot to resist fibrinolysis. These
indices are summarised in Table 1. Soluble P selectin was
measured in citrated plasma by a commercial ELISA kit
(R&D Systems, Abingdon, UK).
Statistics
Our primary hypothesis was of a difference of 0.5 of a
standard deviation in a test statistic between aspirin users
and warfarin users. In view of our expectation to perform
multiple analyses, we determined that p\ 0.02 at a 1-beta
of 0.90 would be significant, a power calculation that
demands a sample size of 106 (that is, 53 patients in each
of two groups). However, we determined to over-recruit by
20 % (that is, to 128), for additional confidence. The
sample size also allows a multivariate logistic regression
analysis of ten possible variables (that is, five indices from
each laboratory method) versus the two categorical indices
of aspirin or warfarin [21]. A sample size of 128 gives that
1-beta power of 0.8 to defend a correlation coefficient of
0.25 from types 1 and 2 error at 2p\ 0.05 [21]. In each
patient group n = 64 brings the power of 1-beta = 0. 8 and
p\ 0.05 for a correlation coefficient[0.35. We therefore
recruited consecutive patients with heart failure, coronary
artery disease or atrial fibrillation until this sample size was
achieved in each group. Our secondary hypothesis was that
there was a difference in a test statistic of 0.5 of a standard
deviation between aspirin users with chronic heart failure
and coronary artery disease, and between warfarin users
with chronic heart failure and atrial fibrillation. To satisfy
p\ 0.05 and 1-beta = 0.8, a sample size of 64 is required
in each case [21]. In this secondary hypothesis we deter-
mined we had insufficient power for a robust correlation
analysis. We also determined to recruit a small number of
patients with acute disease (that is, acute heart failure) to
provide a perspective against chronic heart disease.
Data with a normal distribution are presented as mean
and standard deviation and analysed by t test or analysis of
variance. Data with a non-normal distribution are presented
as median and inter-quartile range and analysed by the
Mann-Whitney U test or the Kruskall–Wallis test. Where
appropriate, data were correlated according to Pearson’s or
Table 1 Thromboelastograph and microplate assay indices
Process assessing
Thrombelastograph indices
R time Time from the initiation of the test until the point where the clot begins to form
K time Interval from the split point of the test to the point where the fibrin cross-linking provides enough clot resistance to
produce a 20-mm amplitude
Angle Angle formed by the slope of a tangent line traced from the R time to the K time: reflects the rate at which the clot
forms
Maximum amplitude Maximum amplitude of the clot dynamics, reflecting clot strength
LY30 Percentage of the clot that has lysed 30 min after the time of the maximum amplitude
Microplate assay indices
Lag time Time from the initiation of the test to the point where the clot begins to form
Rate of clot
formation
Change in optical density over time from the beginning of clot formation (i.e. the end of the lag time) to the point of
maximum optical density
Maximum optical
density
Maximum optical density, reflecting clot thickness
Rate of clot
dissolution
Reduction in optical density from maximum to the plateau phase, divided by the time between the two points
T50 Time for 50 % of the clot to lyse
Thrombelastograph definitions as provided by manufacturer. Full details of the microplate assay indices are presented in Ref. [15]. See also
Fig. 1
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Spearman’s method. Differences between three or more
groups were sought by Tukey’s post-hoc test. Categorical
indices were analysed by the Chi squared test. To deter-
mine which of the thrombelastograph or microplate assay
indices were most closely associated with use of aspirin or
warfarin, a multivariate logistic regression analysis was
performed. All analyses were performed on Minitab release
16 (Minitab, Coventry, UK).
Results
Table 2 shows clinical, demographic and routine labora-
tory data on the 181 patients with different forms of heart
disease and on different medications. Table 3 shows data
from patients with stable cardiovascular disease (i.e.
excluding acute heart failure) on either of the two modes of
antithrombotic therapy (antiplatelet vs anticoagulant). Of
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Fig. 1 The Microplate assay. a Thrombogenesis. The plot shows
changes in optical density as the fibrin clot forms. Triplicate plots are
shown. b Fibrinolysis. The plot shows changes in optical density as the
fibrin clot forms. Triplicate plots are shown. T100 % is the time to
maximum absorbance, T0 % is the return of the optical denity to near-
baseline. T50 % is (T100 % - T0 %)/2. The slope is the sharpest fall
in optical density over time under the effect of exogenous tPA,
effectively the reverse of the rate of clot formation in (a)
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those on aspirin, 44 had coronary artery disease and 25 had
chronic heart failure. Of those on warfarin, 32 had chronic
heart failure and 60 had atrial fibrillation. Patients on
warfarin were older than those on aspirin.
In testing our primary hypothesis, all five thrombelas-
tograph indices were markedly different between the anti-
thrombotic groups by a factor of greater than 0.5 of a
standard deviation (non-normal data log transformed).
Those on warfarin had longer R and K times, a less steep
Angle, a smaller maximum amplitude and higher LY30.
Only four of the microplate assay indices differed between
the two drug groups. As with the thrombelastograph, the
lag time was longer and the rate of clot formation was
slower, but the maximum optical density was greater in
those on warfarin. Although the rate of clot dissolution was
marginally slower on warfarin, the T50 was not altered. A
recent INR was available on 83 patients being treated with
warfarin (atrial fibrillation n = 47, acute heart failure
n = 7, chronic heart failure n = 29). In this group, INR
correlated weakly with the thrombelastograph R time
(r = 0.25, p = 0.023), the Angle (r = -0.25, p = 0.024)
and the LY30 (r = -0.27, p = 0.013). However, the
sample size of 83 allows only for meaningful correlations
with a coefficient that exceeds 0.3 [22], so that these
relationships may be false positives. Nevertheless, the INR
also correlated with the microplate assay index rate of clot
formation (r = -0.34, p = 0.002), a result we believe is
robust.
Table 2 Clinical, laboratory, demographic and therapeutic features of the participants
Acute heart failure
(n = 20)
Chronic heart failure
(n = 57)
Atrial fibrillation
(n = 60)
Coronary artery disease
(n = 44)
p value
Age (years) 74.9 (10.5) 71.0 (12.1) 71.6 (8.9) (68.7) 0.178
Sex (male/female) 17/3 41/16 42/18 29/21 0.140
BMI (kg/m2) 29.5 (7.0) 29.7 (5.8) 30.2 (8.0) 28.0 (5.5) 0.130
SBP (mmHg) 123 (17) 124 (14) 135 (19) 138 (18) \0.001
DBP (mmHg) 71 (11) 73 (11) 77 (11) 74 (13) 0.130
eGFR (1.73/kg/m2) 49 (17) 57 (20) 61 (14) 68 (14) 0.001
Creatinine (lmol/L) 139 (80) 110 (37) 100 (31) 87 (22) \0.001
CAD (n) 20 45 0 44 \0.001
AF (n) 10 36 60 0 \0.001
HF (n) 20 57 0 0 \0.001
Diabetes (n) 11 29 21 19 0.195
Antithrombotic therapy
Antiplatelet (n) 10 25 0 44 \0.001
Warfarin (n) 10 32 60 0 \0.001
INR (in those on
warfarin)
2.1 (0.3)
(n = 7)
2.3 (0.7)
(n = 29)
2.5 (0.7)
(n = 47)
– 0.324
LMWH (n) 10 0 0 0 –
Other medications
ACEI/ARB (n) 18 50 34 33 \0.001
CCB (n) 8 7 19 22 \0.001
Beta-blocker (n) 18 40 42 25 0.112
Aldo-anta (n) 10 23 5 2 \0.001
Loop diuretic (n) 20 42 18 11 \0.001
Statin (n) 18 43 37 37 0.019
Oral nitrates (n) 9 8 7 13 0.003
Hydralazine (n) 1 2 0 0 \0.001
Digoxin (n) 7 13 18 0 0.001
Data presented as mean and standard deviation, median and interquartile range, or number (%) of subjects. p value by analysis of variance or the
Chi squared test
CHF chronic heart failure, AHF acute heart failure, CAD coronary artery disease, AF atrial fibrillation, BMI body mass index, SBP systolic blood
pressure, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, INR international normalised ratio, ACE/ARB angiotensin
converting enzyme inhibitor/angiotensin-receptor blocker, CCB calcium channel blocker, Aldo-Anta aldosterone antagonist
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The multivariate regression analysis of data from
patients with stable cardiovascular disease is shown in
Table 4. Of the thrombelastograph indices, the R time,
LY30 and maximum amplitude were all independently
related to the nature of the antithrombotic (i.e. aspirin or
warfarin). Similarly, of the microplate assay indices, the
rate of clot formation, rate of clot dissolution, the lag time
and maximum optical density were all independently
related to the nature of the antithrombotic. Putting together
those indices above in a third analysis, only microplate
assay indices rate of clot formation, rate of clot dissolution
and maximum optical density were independently related
to the nature of the antithrombotic.
Table 5 shows research indices in patients on aspirin.
The thrombelastograph R time was longer in the acute
heart failure group, but was no different between chronic
heart failure and coronary artery disease. There were dif-
ferences in all five microplate assays indices between the
three groups, and most of these were in the acute heart
failure groups compared to coronary artery disease and
chronic heart failure. The maximum optical density was
higher in acute heart failure than in both chronic heart
failure and coronary artery disease. The rate of clot dis-
solution was slowest in acute heart failure than in both
chronic heart failure and coronary artery disease, and the
T50 % was longer in acute heart failure than in the other
two groups. However, the lag time was markedly longer
(by a mean of 90 s [29 %]) in chronic heart failure com-
pared to coronary artery disease (p\ 0.001). Similarly, the
rate of clot formation was markedly slower (by a mean of
47.5 %) in chronic heart failure compared to coronary
artery disease (p\ 0.001).
Table 6 shows research indices in patients on antico-
agulants. There were no significant differences in any
thrombelastograph index between the three groups. How-
ever, maximum amplitude was marginally greater (by
7.4 %, p = 0.033) in chronic heart failure compared to
atrial fibrillation, despite no difference in the INR (chronic
heart failure 2.3 (0.7), atrial fibrillation 2.5 (0.7),
p = 0.317). Regarding the microplate assay indices, the
rate of clot formation and rate of clot dissolution were both
slower, and the maximum optical density was higher in
acute heart failure compared to both chronic heart failure
and atrial fibrillation.
Soluble P selectin was 9.8 (7.6–11.2) ng/mL in acute
heart failure, 9.0 (6.8–11.8) ng/mL in chronic heart fail-
ure, 9.6 (7.6–10.7) ng/mL in atrial fibrillation, and 8.6
(6.8–10.0) ng/mL in coronary artery disease (p = 0.31).
Levels of soluble P selectin failed to correlate signifi-
cantly with any index of renal function, thrombogenesis
Table 3 Analysis according to
anti-thrombotic therapy in
patients with
stable cardiovascular disease
Index Aspirin (n = 69) Warfarin (n = 92) p value
Age (years) 68.1 (11.3) 72.5 (10.0) 0.011
Sex (male/female) 47/22 62/30 0.922
SBP (mmHg) 133 (17) 131 (19) 0.361
DBP (mmHg) 73 (13) 75 (11) 0.612
eGFR (1.73/kg/m2) 65 (18) 59 (15) 0.080
Creatinine (lmol/L) 96 (33) 103 (31) 0.163
BMI (kg/m2) 28.3 (5.3) 30.2 (7.4) 0.080
Diabetes (yes/no) 35/34 34/58 0.081
Thrombelastograph indices
R time (min) 5.3 (4.4–6.5) 6.5 (5.5–8.7) \0.001
K time (min) 1.4 (1.2–1.8) 1.8 (1.4–2.3) 0.001
Angle () 67.1 (7.5) 62.3 (8.7) \0.001
Maximum amplitude (mm) 67.7 (4.3) 63.6 (10.7) 0.001
LY30 (%) 0.5 (0.1–1.4) 1.0 (0–0.7) 0.006
Microplate assay indices
Lag time (min) 6.35 (2.58) 8.57 (3.38) \0.001
Rate of clot formation (OD units/s) 25.2 (11.4) 17.7 (9.5) \0.001
Maximum optical density (OD units) 0.35 (0.11) 0.40 (0.10) 0.012
Rate of clot dissolution (units/s) 42.1 (13.7) 47.5 (18.1) 0.043
T50 (min) 3.42 (0.77) 3.32 (0.85) 0.527
Data presented as mean and standard deviation, median and interquartile range, or number (%) of subjects.
p value by t test, Mann–Whitney or Chi squared test
SBP systolic blood pressure, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, LY30
lysis at 30 min, T50 time for 50 % of the clot to lyse
Y. C. Lau et al.
123
Table 5 Research indices in patients on aspirin
Index Acute heart failure
(n = 10)
Chronic heart failure
(n = 25)
Coronary artery disease
(n = 44)
p value
Thromboelastograph indices
R time (min) 6.9 (2.9)a 6.0 (1.7) 5.2 (1.3) 0.017
K time (min) 2.0 (1.1) 1.5 (0.6) 1.0 (0.6) 0.136
Angle () 62.0 (11.1) 66.8 (8.6) 67.3 (6.1) 0.161
Maximum amplitude (mm) 67.2 (9.6) 67.8 (4.2) 67.7 (4.4) 0.948
LY30 (%) 0.4 (0–1.32) 0.5 (0.05–1.55) 0.5 (0.07–1.4) 0.843
Microplate assay indices
Lag time (min) 7.3 (4.5–15.4) 6.7 (5.7–16.7) 5.2 (4.5–6.0)b \0.001
Rate of clot formation (OD units/s) 39.0 (7.0)c 20.0 (8.0)c 29.4 (12.0)c \0.001
Maximum optical density (OD
units)
0.55 (0.16) 0.33 (0.13)d 0.38 (0.08)d \0.001
Rate of clot dissolution (OD units/s) 25.9 (3.4) 39.0 (13.7)e 44.5 (13.4)e \0.001
T50 (min) 4.8 (0.55) 3.2 (0.9)d 3.6 (0.6)d \0.001
Data presented as mean and standard deviation, median and interquartile range, or number (%) of subjects. p value by analysis of variance,
between groups by Tukey’s post-hoc test
LY30 lysis at 30 min, T50 time for 50 % of the clot to dissolve
a Higher than in coronary artery disease
b Lower than in acute heart failure and chronic heart failure
c Difference significant between all three groups
d Lower than in acute heart failure
e Higher than in acute heart failure
Table 4 Logistic regression of thrombelastograph and microplate assay indices versus anti-platelet or anticoagulant therapy
Predictor Coefficient SE Coef Z p Odds ratio (95% CI)
Thromboelastograph indices alone
R time 0.551343 0.158764 3.47 0.001 1.74 (1.27, 2.37)
LY30 -0.584913 0.235369 -2.49 0.013 0.56 (0.35, 0.88)
MA -0.111962 0.047035 -2.38 0.017 0.89 (0.82, 0.98)
Angle 0.086552 0.062208 1.39 0.164 1.09 (0.97, 1.23)
K time 0.265357 0.682708 0.39 0.698 1.30 (0.34, 4.97)
Microplate assay indices alone
RCF -0.124420 0.028851 -4.31 \0.001 0.88 (0.83, 0.93)
RCD 0.053695 0.017064 3.15 0.002 1.06 (1.02, 1.09)
L time 0.004334 0.001414 3.07 0.002 1.00 (1.00, 1.01)
MOD 0.071971 0.025785 2.79 0.005 1.07 (1.02, 1.13)
T50 0.002828 0.004716 0.60 0.549 1.00 (0.99, 1.01)
Thrombelastograph and microplate assay indices
MPA RCF -0.109234 0.028386 -3.85 \0.001 0.90 (0.85, 0.95)
MPA RCD 0.059916 0.017783 3.37 0.001 1.06 (1.03, 1.10)
MPA MOD 0.056458 0.026578 2.12 0.034 1.06 (1.00, 1.11)
TEG LY30 -0.494109 0.253729 -1.95 0.051 0.61 (0.37, 1.00)
TEG R time 0.259616 0.134682 1.93 0.054 1.30 (1.00, 1.69)
MPA L time 0.002744 0.001634 1.68 0.093 1.00 (1.00, 1.01)
TEG MA -0.067848 0.042077 -1.61 0.107 0.93 (0.86, 1.01)
TEG thrombelastograph, MPA microplate assay, MA maximum amplitude, MOD maximum optical density (both tests of clot integrity), L time
lag time, RCF rate of clot formation, RCD rate of clot dissolution, T50 time for 50 % of the clot to be lysed, LY30 clot autolysis at 30 min (all
three are measures of fibrinolysis)
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or fibrinolysis (data not shown). Excluding acute heart
failure patients, levels were 8.4 (7.5–11.1) ng/mL in those
patients on aspirin (including all those with coronary
artery disease) and 9.6 (6.7–10.4) ng/mL in those patients
(including all those with atrial fibrillation) on warfarin
(p = 0.0175).
Correlations
With a pre-specified correlation coefficient of 0.25, therewere
no meaningful relationships between any clinical or demo-
graphic index and any laboratory index. Significant correla-
tions between haemostasis indices in the entire group are
shown in Table 7. There were strong (correlation coefficient
(r)[0.6) associations between the thromboelastograph R and
K times, the R time and the Angle, and the K time with the
Angle, but none between any microplate assay index. There
were modest (r 0.35–0.59) associations between thromboe-
lastograph indices maximum amplitude and K time, and
maximum amplitude with the Angle, and between microplate
assay indices rate of clot formation with maximum amplitude
and of the rate of clot formation with T50. There were weak (r
0.25–0.34) but statistically significant associations between
microplate assay indices lag time and rate of clot formation,
and between the rate of clot dissolution and the T50. In
seeking relationships between thrombelastograph indices and
microplate assay indices, the microplate assay lag time cor-
related modestly with the thrombelastograph R time, the K
time, and inversely with the Angle.
Discussion
In this study, our principal findings are that, although often
assessing similar aspects of thrombogenesis and fibrinoly-
sis, the thrombelastograph and microplate assay methods
provide markedly different outcomes. For example, in the
regression analysis, the two microplate assay indices of rate
of clot formation and rate of clot dissolution were inde-
pendent predictors of the nature of the anti-thrombotic, and
in the aspirin users, all five microplate assay indices (but
none of the thrombelastograph indices) varied between
patient groups.
Thrombosis in cardiovascular disease still occurs despite
best anti-thrombotic therapy, prompting research into
pathophysiology and the effects of drugs on mechanisms of
thrombosis. Although valuable, existing laboratory mea-
sures for assessing haemostasis, including the thrombelas-
tograph, have limitations [9, 11, 19, 23–25]. The microplate
assay has some features in common with the thrombelas-
tograph, and has other features, such as the assessment of
fibrinolysis initiated by exogenous tPA [15]. However, there
are several alternative assays that also assess fibrin clot
formation and fibrinolysis, some of which are performed in a
micro-titre plate [13, 14, 26–28]. For example, that of
Talens et al. [27] produces a tPA-mediated fibrinolysis time
of over 80 min, whilst Zabczyk et al. [28] reported how
warfarin rapidly influences indices of clot integrity in
patients with atrial fibrillation. Soluble P selectin is known
to be increased in all major cardiovascular disease [29–31],
Table 6 Research indices in patients on warfarin
Index Acute heart failure (n = 10) Chronic heart failure (n = 32) Atrial fibrillation (n = 60) p value
Thrombelastograph indices
R time (min) 6.1 (4.6–9.2) 6.6 (5.4–9.7) 6.5 (5.5–7.9) 0.564
K time (min) 1.3 (1.0–2.3) 1.8 (1.3–2.4) 1.8 (1.4–2.3) 0.240
Angle () 61.7 (17.2) 63.0 (9.6) 61.8 (8.2) 0.864
Maximum amplitude (mm) 65.4 (13.3) 66.6 (8.3) 62.0 (11.5) 0.144
LY30 (%) 0.15 (0–0.19) 0.2 (0–0.47) 0.1 (0–0.82) 0.917
Microplate asay indices
Lag time (min) 8.2 (7.0–12.9) 7.4 (6.4–10.3) 7.9 (6.8–10.0) 0.553
Rate of clot formation (OD units/s) 37.6 (22.7–48.5)a 17.5 (11.3–26.4) 15.1 (10.8–20.2) 0.002
Maximum optical density (OD units) 0.53 (0.20)a 0.38 (0.11) 0.41 (0.10) 0.002
Rate of clot dissolution (OD units/s) 18.8 (8.5)b 49.4 (18.9) 46.4 (17.7) \0.001
T50 (min) 3.7 (1.6) 3.35 (0.9) 3.3 (0.8) 0.553
Data presented as mean and standard deviation, median and interquartile range, or number (%) of subjects. p value by analysis of variance,
between groups by Tukey’s post-hoc test
LY30 lysis at 30 min, T50 time for 50 % of the clot to dissolve
a Higher than in chronic heart failure and atrial fibrillation
b Lower in acute heart failure than in chronic heart failure and coronary artery disease
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and in our hands, do not differ between those with atrial
fibrillation, coronary artery disease or heart failure.
Methodological aspects
In our study of 181 patients with various cardiovascular
diseases and on different therapies, three thrombelas-
tograph indices (R time, K time and Angle) inter-correlated
strongly suggesting they measure similar aspects of
thrombogenesis, whilst two pairs of indices (maximum
amplitude with K time and Angle) correlated modestly,
suggesting they too share certain features of haemostasis.
In the microplate assay, the rate of clot formation corre-
lated with the maximum optical density (which is plausible
as they respectively mark the rate of clot formation and its
density once formed). However, the same strength of cor-
relation between the rate of clot formation and the T50 is
less easy to explain but may reflect clot structure. The
thrombelastograph R time and microplate assay lag time
correlated modestly, suggesting they too share common
features, these being those related to clot formation.
Unsurprisingly, all indices related to clot formation and
integrity were different in those on aspirin (and so an
undisturbed coagulation pathway) compared to warfarin
(with a disturbed coagulation pathway). The finding that
soluble P selectin is lower in those on aspirin confirms
other data [32, 33] and the effect of this drug on platelets.
Delayed initiation of thrombogenesis in warfarin use was
apparent with prolonged TEG R and K times and the
microplate lag time. Similarly, slower clot growth was
demonstrated by altered thrombelastograph Angle and the
microplate assay rate of clot formation. Use of warfarin
provided a less robust whole blood clot (thrombelastograph
maximum amplitude), but the higher microplate assay
maximum optical density result on warfarin implies a
denser fibrin clot than in those using aspirin. The reasons
for this are unclear but are likely to relate to an effect of
blood cells on the thrombelastograph assay. Of the 83
patients taking warfarin, the INR correlated most strongly
with the microplate assay rate of clot formation, but less so
with the thrombelastograph R time and the Angle, all of
which seems likely as warfarin impairs clot formation. To
some extent this latter result is counter to the report by
Franchi et al. [19] of 100 patients on warfarin, who found
the correlation between the INR and thrombelastograph to
be barely not significant (r = 0.19, p = 0.06), which may
be due to difference in patients between the two studies.
Franchi et al. [19] also failed to significantly correlate the
INR with other thrombelastograph indices, and taken
together, this may because of the combined effects of all
Table 7 Spearman correlates between haemostasis indices in 181 patients with cardiovascular disease
R time K time Angle Maximum amplitude
Thrombelastograph indices
LY30 -0.13, 0.077 -0.20, 0.009 0.25, 0.001 -0.13, 0.097
Maximum amplitude -0.24, 0.001 -0.50,\0.001 0.56,\0.001
Angle -0.64,\0.001 -0.87,\0.001
K time 0.69,\0.001
Microplate assay indices Lag time Rate of clot formation Maximum optical density Rate of clot formation
Microplate assay indices
T50 -0.05, 0.525 0.35,\0.001 0.14, 0.073 -0.25, 0.001
Rate of clot dissolution -0.16, 0.039 0.04, 0.607 0.08, 0.284
Maximum optical density 0.13, 0.104 0.35,\0.001
Rate of clot formation -0.28,\0.001
Microplate assay indices Thrombelastograph indices
R time K time Angle Maximum amplitude LY30
Thromboelastograph indices vs microplate indices indices
Lag time 0.47,\0.001 0.37,\0.001 -0.35,\0.001 -0.09, 0.257 -0.18, 0.02
Rate of clot formation -0.23, 0.002 -0.22, 0.004 0.18, 0.021 0.17,0.027 0.19, 0.012
Maximum optical density 0.08, 0.315 -0.08, 0.334 0.09, 0.271 0.13, 0.085 -0.07, 0.371
Rate of clot dissolution -0.10, 0.195 0.02, 0.807 0.02, 0.801 -0.08, 0.326 0.03, 0.652
T50 -0.06, 0.417 -0.02, 0.789 0.01, 0.850 0.14, 0.066 -0.03, 0.740
Data are Spearman correlation coefficient (r) and p value
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three types of blood cells on clot formation and dissolution
(such as the release of platelet-stimulating ADP by red
cells, and expression of pro-coagulant tissue factor by
monocytes). Indeed, one way of improving the thrombe-
lastograph is to modify the process by adding exogenous
tissue factor to the kaolin to accelerate the process of clot
formation [19]. However, the correlation we found between
the INR and TEG LY30 index may be explained as a
weaker clot (marked by a high INR) being more suscep-
tible to autolysis.
Although all five thrombelastograph indices were dif-
ferent between the two antithrombotic classes, in multi-
variate analysis only the R time remained a strong
significant independent predictor. This can be accounted
for by the many strong or moderate correlations between
certain of these five indices (Table 7). This is in contrast to
the four microplate assay indices, which were all retained
in multivariate analysis, implying each offer a different
independent aspect of clot formation. In a combined
analysis, the two microplate assay indices of rate of clot
formation and rate of clot dissolution both remained
strongly linked to the use of warfarin or aspirin, whilst the
thrombelastograph R time was eliminated.
Clinical aspects: aspirin users
Seventy-nine patients were taking aspirin, and are therefore
expected to have an ‘intact’ coagulation pathway. All five
microplate assay indices were markedly (p\ 0.001) dif-
ferent between the three patient groups, but only one
thrombelastograph index (the R time) was marginally
(p = 0.017) different between the three groups. However,
a great deal of this variability may be due to the gross
abnormalities in the acute heart failure patients, all of
whom were in-patients and therefore in need of enhanced
care, and of whom half were being treated with a low
molecular weight heparin to prevent inpatient venous
thromboembolism. In comparing only those with chronic,
stable disease (i.e. chronic heart failure v coronary artery
disease), thrombogenesis in plasma (as defined by the
microplate assay lag time) was more rapid in coronary
artery disease than in chronic heart failure. This may be
because, in these patients, the pathophysiology of their
coronary artery disease is more thrombogenic than those
with chronic heart failure, none of whom had a history of,
or overt, coronary artery disease.
A further possible effect on these indices is the effect of
other classes of pharmaceuticals such as nitrates and sta-
tins. In addition, coronary artery disease patients had a
more rapid rate of clot formation than the chronic heart
failure patients. This also imply that patients with coronary
artery disease on aspirin are at increased risk of thrombosis
compared to chronic heart failure patients on aspirin, and
perhaps soluble platelet products such as beta-throm-
boglobulin may take part in plasma thrombogenesis [34,
35]. The difference in rate of clot formation in the chronic
heart failure group compared to the coronary artery group
suggests it may have potential as a marker of thrombo-
genicity in aspirin users, as does the INR in warfarin users.
Clinical aspects: warfarin users
One hundred and twelve patients were taking warfarin, and
will therefore have a ‘disrupted’ coagulation pathway.
Only the microplate assay indices rate of clot formation,
maximum optical density and rate of clot dissolution were
different between the groups. Once more, a great deal of
this variability may be due to the gross abnormalities in
haemostasis among the acute heart failure patients. It
suggests that acute heart failure patients possess greater
thrombotic potential (faster rate of clot formation), and
form thicker clots (greater maximum optical density),
which are more resistant to exogenous tPA-induced fibri-
nolysis (with slower rate of clot dissolution). However, we
speculate that a great deal of these differences are due to
low molecular weight heparin therapy in 50 % of the acute
heart failure patients, reflecting the data of Incampo et al.
[14] who, using a thrombelastograph and a turbidimetry
assay, showed the effects of this anticoagulant on indices of
haemostasis. In comparing only those with chronic,
stable disease (i.e. chronic heart failure v atrial fibrillation),
those with chronic heart failure generated a slightly more
robust clot (higher maximum amplitude) than those atrial
fibrillation patients. It may also be the case that the
thrombelastograph and/or the microplate assay could be
used, if necessary, to assess thrombogenicity in the absence
of an INR. The lack of strong correlations between the INR
and thrombelastograph indices supports the contention of
Franchi et al. [19] that the thrombelastograph is not a
useful tool to evaluate VKA anticoagulant effect, compared
with standard INR measurements, although a modified
rapid technique shows promise.
Thrombelastography and the microplate assay
compared
As the thrombelastograph operates on whole blood and the
microplate assay uses plasma, the two methods are fun-
damentally different. Indeed, thrombelastograph indices
can be directly influenced by platelets [36, 37], and may be
useful in assessing the activity of NOACs [17, 38]. Nev-
ertheless, both techniques measure thrombogenesis, clot
integrity, and fibrinolysis. Several of the thrombelastograph
indices (Angle, R time, K time) provide similar informa-
tion (correlations coefficient [0.56), whereas all of the
microplate assays indices are (by and large) independent of
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each other (correlations coefficients\0.35). Although all
of the thrombelastograph indices, but only four of the
microplate assay indices were different in the presence of
disrupted coagulation, in multivariate analysis, only the
microplate rate of clot formation and rate of clot dissolu-
tion indices were independent predictors of the use of
warfarin, suggesting they may have real value in a clinical
setting.
The microplate lag time and the rate of clot formation
also show promise as clinical tools, being more adverse in
coronary artery disease than in chronic heart failure. This is
surprising as the primary reason for a chronic heart failure
patient being on aspirin is because of underlying arterial
disease, as is the case in 80 % of our chronic heart failure
patients. This point is also pertinent as patients with CHF
may be treated with anti-platelets or with warfarin [7], and
so may be relevant in clinical decision-making.
Limitations
We acknowledge several limitations, the principal
methodological one being that of whole blood versus
plasma, in that the latter does not allow discussion of the
effects of cells. Conversely, differences in the certain
indices between two methods may well be due to the cel-
lular components of the blood. Centrifugation was at a
‘standard’ speed and duration (3000 rpm, 20 min) so we
cannot exclude the possibility of the presence of small
platelets or procoagulant platelet microparticles in the
plasma [39]. The thrombelastograph is far easier to operate:
the microplate assay demands technical skill in reagent
preparation and sample processing, although overall the
MPA is far more economical than the thrombelastograph.
From the clinical perspective it is distantly possible some
indices may be influenced by other drugs such as nitrates
and statins. Although renal function differed between
patient groups, this did not associate with any thrombe-
lastograph or microplate assay, despite suggestions that this
may be the case [18, 40]. Finally, we acknowledge that is
important to note that, as shown for other assays assessing
effects of antiplatelet agents which have differences in
technical aspects, even for these assays used in this study,
methodological variations may explain differences in
pharmacodynamics.
Conclusions
As with other related methods [14, 26–28], such as the
rapid-thrombelastograph [19], the microplate assay shows
promise as an alternative tool for dissecting thrombogen-
esis and fibrinolysis in cardiovascular disease, and the
impact of anti-thrombotic therapy. Large prospective
studies in coronary artery disease, heart failure and atrial
fibrillation are required to ascertain the clinical value of
these mechanistic biomarkers for determining the risk of
major cardiovascular events and thromboembolism in heart
disease.
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